Literature DB >> 23794708

Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.

Brent N Rexer1, Carlos L Arteaga.   

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2(+) breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23794708      PMCID： PMC3702635          DOI： 10.1158/0008-5472.CAN-13-0687

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  34 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

3.  Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Authors:  Syed K Mohsin; Heidi L Weiss; M Carolina Gutierrez; Gary C Chamness; Rachel Schiff; Michael P Digiovanna; Chun-Xia Wang; Susan G Hilsenbeck; C Kent Osborne; D Craig Allred; Richard Elledge; Jenny C Chang
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

4.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.

Authors:  B M Ryan; G E Konecny; S Kahlert; H-J Wang; M Untch; G Meng; M D Pegram; K C Podratz; J Crown; D J Slamon; M J Duffy
Journal:  Ann Oncol       Date:  2006-01-10       Impact factor: 32.976

6.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Authors:  F Michael Yakes; Wichai Chinratanalab; Christoph A Ritter; Walter King; Steven Seelig; Carlos L Arteaga
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

Authors:  Anindita Chakrabarty; Neil E Bhola; Cammie Sutton; Ritwik Ghosh; María Gabriela Kuba; Bhuvanesh Dave; Jenny C Chang; Carlos L Arteaga
Journal:  Cancer Res       Date:  2012-11-29       Impact factor: 12.701

8.  Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Authors:  Christoph A Ritter; Marianela Perez-Torres; Cammie Rinehart; Marta Guix; Teresa Dugger; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

9.  Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.

Authors:  Li Zhao; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

10.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Authors:  L Arnould; M Gelly; F Penault-Llorca; L Benoit; F Bonnetain; C Migeon; V Cabaret; V Fermeaux; P Bertheau; J Garnier; J-F Jeannin; B Coudert
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640
View more
  21 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

Review 2.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

3.  hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.

Authors:  P Trono; F Di Modugno; R Circo; S Spada; A Di Benedetto; R Melchionna; B Palermo; S Matteoni; S Soddu; M Mottolese; R De Maria; P Nisticò
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 4.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

5.  Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Authors:  Katherine L Pogue-Geile; Nan Song; Jong-Hyeon Jeong; Patrick G Gavin; Seong-Rim Kim; Nicole L Blackmon; Melanie Finnigan; Priya Rastogi; Louis Fehrenbacher; Eleftherios P Mamounas; Sandra M Swain; D Lawrence Wickerham; Charles E Geyer; Joseph P Costantino; Norman Wolmark; Soonmyung Paik
Journal:  J Clin Oncol       Date:  2015-01-05       Impact factor: 44.544

6.  Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathways.

Authors:  Ming Wang; Zhi-Jun Shu; Ying Wang; Wei Peng
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 7.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

8.  Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

Authors:  Ingrid A Mayer
Journal:  Curr Breast Cancer Rep       Date:  2015-10-10

9.  Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.

Authors:  Todd A Duncombe; Chi-Chih Kang; Santanu Maity; Toby M Ward; Mark D Pegram; Niren Murthy; Amy E Herr
Journal:  Adv Mater       Date:  2015-11-16       Impact factor: 30.849

10.  A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.

Authors:  Iryna O Zubovych; Anirudh Sethi; Aditya Kulkarni; Vural Tagal; Michael G Roth
Journal:  Mol Cancer Ther       Date:  2015-12-14       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.